Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.
Saved in:
| Title: | Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. |
|---|---|
| Authors: | Nassar AH; Department of Hematology/Oncology, Yale New Haven Hospital, New Haven, CT, 06510, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Abou Alaiwi S; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Baca SC; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Adib E; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Corona RI; Women's Cancer Research Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Fonseca MAS; Women's Cancer Research Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Spisak S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA., El Zarif T; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Tisza V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA., Braun DA; Department of Hematology/Oncology, Yale New Haven Hospital, New Haven, CT, 06510, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA., Du H; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA., He M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Flaifel A; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA., Alchoueiry M; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA., Denize T; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA., Matar SG; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA., Acosta A; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA., Shukla S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA., Hou Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA., Steinharter J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Bouchard G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Berchuck JE; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., O'Connor E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Bell C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Nuzzo PV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Mary Lee GS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Signoretti S; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA., Hirsch MS; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA., Pomerantz M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Henske E; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Gusev A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; McGraw/Patterson Center for Population Sciences, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Lawrenson K; Women's Cancer Research Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Choueiri TK; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA. toni_choueiri@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. toni_choueiri@dfci.harvard.edu., Kwiatkowski DJ; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA. dk@rics.bwh.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. dk@rics.bwh.harvard.edu., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. mfreedman@partners.org.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. mfreedman@partners.org.; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA. mfreedman@partners.org. |
| Source: | Nature communications [Nat Commun] 2023 Jan 21; Vol. 14 (1), pp. 346. Date of Electronic Publication: 2023 Jan 21. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-023-35833-5 |
